Company Overview and News
David Einhorn's hedge fund Greenlight Capital has had a rough 2018. They're now down 25.7% for the year. During the quarter, they exited the last of their longstanding Apple (AAPL) position at $228 per share. They feel their AAPL thesis that was once differentiated has now become consensus and the valuation of 17x forward earnings is "much less enticing and we are somewhat worried about Chinese retaliation against America's trade policies.
BT.A TDG BTGOF ATUS MLM ALV.WI BT
BT Group (BT) is a telecommunications firm based in the UK that offers both residential and commercial broadband services as well as mobile phone service. BT Group is a strong buy and offers a case study in what a well-managed business and a safe investment should resemble. The firm operates in the UK which is an advantageous location to operate a telecom firm in since the area has a higher level of population density than the United States.
BT.A BTGOF BT
Rubis will sell its Iranian division to comply with the US Sanctions and has recorded an impairment charge.
FLOW GLCNF RDSB RDSA WRDEF BINCY MBSRF INSW RYDAF BPOSY PMOIY BT.A RDS.B RDS.A MBSRY PMOIF RBSFY BTGOF ATRBF PMO NSW BT BPOSF ABI RYDBF INGIF FLTDF INSW.WI GLNCY
LONDON – D-Wave Systems Inc., a Canadian manufacturer of quantum computers, is making its powerful machines and software development tools available for free through a new internet-based platform.
VLKAF BT.A GOOGL BTGOF GOOG BT
2018-09-24 reuters - 1
Sept 24 (Reuters) - Britain’s FTSE 100 index is seen opening 27 points lower at 7,464 on Monday, according to financial bookmakers, with FTSE 100 futures down 0.22 percent ahead of the cash market open.
BT.A FOX BLT ABX 500413 WPPGF BHPBF RGORF BTGOF WPPGY GOLD RRS THOMASCOOK GOLD BT BHP BBL BHP BHPLF FOXA ABX
LONDON (Reuters) - BT Group (BT.L) is in advanced talks to appoint payment technology provider Worldpay’s (WP.N) outgoing co-chief executive Philip Jansen as its new chief executive, Sky News reported on Saturday.
BT.A BTGOF BT
BT Group is in advanced talks to appoint payment technology provider Worldpay's outgoing co-chief executive Philip Jansen as its new chief executive, Sky News reported on Saturday.
BT.A BTGOF BT
LONDON, Sept 22 (Reuters) - BT Group is in advanced talks to appoint payment technology provider Worldpay’s outgoing co-chief executive Philip Jansen as its new chief executive, Sky News reported on Saturday.
BT.A BTGOF BT
Total's share price has performed well since the company was added to the Nest Egg Portfolio.
SGPEF WOPEF FLOW DIREN RDSB RDSA WRDEF ENGIY BINCY SGPEY MBSRF MS RYDAF BPOSY VLKAY BPOST LNAGF INTU BT.A RDS.B RDS.A MBSRY BTGOF CCRGF WPL WOPEY BPOSF BT PWOPY ENGQF RYDBF
2018-09-04 sec.gov - 2
2018-08-19 seekingalpha - 1
Postal companies are still being ignored (or punished) by the market. Sometimes that’s deserved, but other times it seems to be more sentiment-based than fundamentals based. Yes, the ‘normal’ old-school post market is shrinking, but companies have been trying to tap into new sources of revenue (CTT Correios de Portugal (OTC:CTTPY) has started a bank), or are trying to improving the sorting and handling system to increase the volume of parcels.
DB FLOW XOM RDSB OCI RDSA WRDEF HIBRF BINCY CTTPY OCINF MBSRF RYDAF BPOSY BT.A RDS.B RDS.A MBSRY BTGOF ATASF BT BPOSF HBRN ATASY RYDBF FLTDF
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to BT / BT Group Plc on message board site Silicon Investor.
as of ET